PHARVARIS NV (PHVS)

NL00150005Y4 - Common Stock

18.53  -0.01 (-0.05%)

After market: 18.53 0 (0%)

PHARVARIS NV

NASDAQ:PHVS (1/3/2025, 8:00:01 PM)

After market: 18.53 0 (0%)

18.53

-0.01 (-0.05%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%-32.76%
Sales Q2Q%N/A
CRS19.28
6 Month11.29%
Overview
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)N/A N/A
Ins Owners9.49%
Inst Owners57.34%
Market Cap1.00B
Shares54.01M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts84.29
Short Float %0.47%
Short Ratio1.79
IPO02-05 2021-02-05
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

PHVS Daily chart

Company Profile

Pharvaris NV operates as a clinical-stage biopharmaceutical company. The company is headquartered in Leiden, Zuid-Holland and currently employs 82 full-time employees. The company went IPO on 2021-02-05. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).

Company Info

PHARVARIS NV

J.H. Oortweg 21

Leiden ZUID-HOLLAND

CEO: Berndt Modig

Employees: 82

Website: https://pharvaris.com/

PHVS News

News Image15 days ago - Market News VideoPharvaris (PHVS) Shares Cross Above 200 DMA
News Image2 months ago - Pharvaris N.V.Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
News Image2 months ago - Pharvaris N.V.Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Positive long-term extension data highlighting the differentiated profile of deucrictibant for the prevention and treatment of HAE attacks presented at...

News Image2 months ago - Pharvaris N.V.Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
News Image2 months ago - Pharvaris N.V.Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference

ZUG, Switzerland, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2...

News Image2 months ago - Market News VideoPHVS Makes Notable Cross Below Critical Moving Average

PHVS Twits

Here you can normally see the latest stock twits on PHVS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example